35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Among the processes involved in the breast tumor microenvironment, angiogenesis and inflammation play a central role, and the main factors of these processes are the vascular endothelial growth factor (VEGF), cyclooxygenase 2 (COX-2) and macrophages. Recently, the extract of Euterpe oleracea (açaí), a fruit that is widely found in the Amazon region, already showed antitumorigenic effects in vitro in human breast cancer cell lines. The present study aimed to investigate the effect of açaí on breast cancer using a chemically DMBA (7,12-dimethylbenzanthracene) experimental model.

          Methods

          One day after initiation of treatment with açaí, mammary carcinogenesis was induced in female Wistar rats using a subcutaneous injection of 25 mg/kg of DMBA in the mammary gland. Forty rats were randomized into two groups: treated with 200 mg/kg of either açaí extract or vehicle, via gastric tube for 16 consecutive weeks. After treatment, the tumor was collected for macroscopic, histological and immunohistochemical (VEGF, vascular endothelial growth factor receptor 2 -VEGFR-2, COX-2 and matrix metalloproteinase -MMP-9) analyses; peritoneal fluid was subjected to flow cytometry (F4–80/MAC-2+) and ELISA immunoassay (VEGF, prostaglandin E 2 -PGE 2 and interleukin-10 -IL-10). Heart, liver and kidney samples were collected for histological analysis.

          Results

          After 16 weeks of induction, the mammary carcinoma was confirmed by macroscopic and histological evaluation. Survival analysis indicates that açaí increased the survival ( P = .0002, long-rank test) and reduced the deaths number ( P = .0036, Chi-square test). Açaí treatment decreased the number of inflammatory cells and macrophage positive cells (Mac-2 + F4–80+), as well as promoting a reduction in immunostaining of VEGF, VEGFR-2 and COX-2. The açaí group also exhibited lower concentrations of PGE 2, VEGF and IL-10 compared to the control. The histopathological results of the liver and kidneys showed protective effect of açaí, since in the control group, there was an increase in fibrosis, atypical cells and hemorrhagic microenvironment.

          Conclusion

          The results of this study demonstrated the antiangiogenic and anti-inflammatory potential of açaí, like due to the decreases of the number of activated macrophages, resulting in the inhibition of DMBA carcinogenicity in breast cancer.

          Electronic supplementary material

          The online version of this article (10.1186/s12906-018-2183-z) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Angiogenesis: an organizing principle for drug discovery?

          Angiogenesis--the process of new blood-vessel growth--has an essential role in development, reproduction and repair. However, pathological angiogenesis occurs not only in tumour formation, but also in a range of non-neoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'. By viewing the process of angiogenesis as an 'organizing principle' in biology, intriguing insights into the molecular mechanisms of seemingly unrelated phenomena might be gained. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

            Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.

              Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF-VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF-VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                +55 21 2332-7535 , jessicaperini@yahoo.com.br
                jamilaperini@yahoo.com.br
                karinabaptista@yahoo.com.br
                robertosoaresdemoura@gmail.com
                palumbo@icb.ufrj.br
                thiago.ats@live.com
                pjcsou@ufpa.br
                luiz.nasciutti@histo.ufrj.br
                danielescorsim@yahoo.com.br
                Journal
                BMC Complement Altern Med
                BMC Complement Altern Med
                BMC Complementary and Alternative Medicine
                BioMed Central (London )
                1472-6882
                2 April 2018
                2 April 2018
                2018
                : 18
                : 116
                Affiliations
                [1 ]ISNI 0000 0001 2294 473X, GRID grid.8536.8, Morphological Sciences Program, Biomedical Sciences Institute, , Federal University of Rio de Janeiro, ; Rio de Janeiro, RJ Brazil
                [2 ]Research Laboratory of Pharmaceutical Sciences, West Zone State University, Av Manuel Caldeira de Alvarenga, 1.203, Campo Grande, Rio de Janeiro, RJ 23070-200 Brazil
                [3 ]Program of Post-graduation in Public Health and Environment, National School of Public Health, Oswald Cruz Foundation, Rio de Janeiro, RJ Brazil
                [4 ]GRID grid.412211.5, Department of Pharmacology and Psychobiology, , State University of Rio de Janeiro, ; Rio de Janeiro, RJ Brazil
                [5 ]ISNI 0000 0001 2171 5249, GRID grid.271300.7, Departament of Pharmacy, , Federal University of Pará, ; Belém, PA Brazil
                Article
                2183
                10.1186/s12906-018-2183-z
                5879811
                29609579
                c24b792f-366b-455c-ba4d-d4b6840e3910
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 3 August 2017
                : 21 March 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004586, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro;
                Funded by: FundRef http://dx.doi.org/10.13039/501100004931, Fundação Ary Frauzino para Pesquisa e Controle do Câncer;
                Funded by: FundRef http://dx.doi.org/10.13039/501100002322, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior;
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Complementary & Alternative medicine
                breast cancer,euterpe oleracea,anti-inflammatory,angiogenesis

                Comments

                Comment on this article